Compare Charles Schwab Corporation Common Stock (SCHW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs TG Therapeutics Inc — how do they compare? Charles Schwab Corporation Common Stock trades at $100.17 (market cap $178.33B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 21.6× TG Therapeutics Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.25% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SCHW | TGTX | |
|---|---|---|
Market Cap | $178.33B | $8.26B |
Sector | Financials | Health |
52-Week High | $107.21 | $59.06 |
52-Week Low | $85.35 | $26.39 |
Dividend Yield | 1.25% | — |
Enterprise Value | — | $8.50B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
